サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1606412

去勢抵抗性前立腺市場：治療法別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2024年～2032年

Castrate Resistant Prostate Market, By Therapy, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 260 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
去勢抵抗性前立腺市場：治療法別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2024年～2032年
出版日: 2024年11月04日
発行: AnalystView Market Insights
ページ情報: 英文 260 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

去勢抵抗性前立腺市場は2023年に89億454万米ドルと評価され、2024年から2032年にかけてCAGR 8.70%で拡大

去勢抵抗性前立腺市場 - 市場力学

前立腺がんの早期発見の増加が市場成長を促進すると予想されます。

早期発見により、前立腺がんの初期段階におけるアンドロゲン除去療法（ADT）や代替治療による迅速な介入が容易になります。とはいえ、初期治療にもかかわらず去勢抵抗性前立腺がん（CRPC）に進行する症例もあるが、早期介入が患者の生存期間の延長に寄与する可能性もあります。前立腺がんは重大な健康リスクをもたらす可能性があるが、この病気と診断された男性の大多数はがんに倒れることはないです。米国がん協会によると、2024年の米国における前立腺がんの予測は、この疾患に起因する約299,010人の新規患者と約35,250人の死亡者数を示しています。さらに、新規治療法の出現と診断技術の進歩が、市場拡大の新たな道を開く可能性があります。しかし、新興国市場では認知度や診断能力が限られているため、市場成長の妨げになる可能性があります。

去勢抵抗性前立腺市場 - 主要洞察

弊社リサーチアナリストの分析によると、世界市場は予測期間（2024年～2032年）に約8.70%のCAGRで毎年成長すると推定されます。

薬剤クラス別では、2023年はホルモン療法がトップでした。

地域別では、北米が2023年の売上高でトップでした。

去勢抵抗性前立腺市場 - セグメンテーション分析：

世界の去勢抵抗性前立腺市場は、治療法、流通チャネル、地域に基づいてセグメント化されます。

市場は治療タイプによって、化学療法、ホルモン療法、免疫療法、放射線療法の4つに区分されます。ホルモン療法は市場で優位な地位を占めています。この治療法は、前立腺がんの進行が主にアンドロゲンホルモン、特にテストステロンに影響されることから、去勢抵抗性前立腺がん（CRPC）の管理に不可欠です。

市場は流通チャネルによって、病院、がん治療センター、小売薬局、オンライン薬局の4つのカテゴリーに区分されます。病院とがん治療センターは、高度で専門的な治療を提供する上で引き続き重要な役割を果たしています。一方、小売薬局とオンライン薬局は、外来治療管理を選択する患者が増加していることから、ますます重要性を増しています。

去勢抵抗性前立腺市場 - 地理的洞察

同市場は、北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカを含む広範な地域にまたがっています。これらの地域は、事業活動に貢献している国に基づいてさらに分類されます。北米は、主にヘルスケア支出の増加と治療オプションへのアクセス強化により、市場拡大をリードしています。北米、特に米国とカナダにおけるヘルスケア支出の大幅な増加は、CRPC市場の成長にとって極めて重要です。ヘルスケア予算の増加は、CRPCに対する最先端の治療、高度な診断ツール、革新的な治療への投資を促進します。National Health Expendituresによると、米国のヘルスケア支出は2022年に4.1％増の4兆5,000億米ドルとなり、2021年の3.2％増を上回ったが、2020年の10.6％増と比べるとかなり低い水準にとどまっています。欧州は、外来治療への嗜好の高まりに牽引され、市場成長第2位の地域となっています。

去勢抵抗性前立腺市場 - 競合情勢：

去勢抵抗性前立腺がん（CRPC）市場は、革新的な治療法の開発と商業化に取り組む製薬企業やバイオ医薬品企業による大きな競争が特徴です。すでに確立された治療法が数多く存在するため、市場は飽和しつつあり、各社はより大きなシェアを確保するために精力的なマーケティング戦略や販売促進戦略に取り組んでいます。併用療法、遺伝子プロファイリング、免疫腫瘍学が重視されるようになり、競合環境はさらに激化すると予想されます。

目次

第1章 去勢抵抗性前立腺市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 去勢抵抗性前立腺の主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 去勢抵抗性前立腺の産業調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 去勢抵抗性前立腺市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 去勢抵抗性前立腺市場情勢

  • 去勢抵抗性前立腺市場シェア分析、2022年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 去勢抵抗性前立腺市場 - 治療法別

  • 概要
    • セグメントシェア分析 - 治療法別
    • 化学療法
    • ホルモン療法
    • 免疫療法
    • 放射線治療

第8章 去勢抵抗性前立腺市場 - 流通チャネル別

  • 概要
    • セグメントシェア分析 - 流通チャネル別
    • 病院
    • がん治療センター
    • 小売薬局
    • オンライン薬局

第9章 去勢抵抗性前立腺市場 - 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第10章 主要ベンダー分析 - 去勢抵抗性前立腺産業

  • 競合ダッシュボード
  • 企業プロファイル
    • Sanofi
    • Johnson &Johnson Services, Inc.
    • Pfizer, Inc.
    • Astellas Pharma, Inc.
    • Bayer AG
    • Phinergy
    • その他

第11章 アナリストの全方位展望

目次
Product Code: ANV4182

REPORT HIGHLIGHT

The Castrate-Resistant Prostate Market was valued at USD 8,904.54 million in 2023 and expanded at a CAGR of 8.70% from 2024 to 2032.

Castration-resistant prostate cancer (CRPC) represents an advanced stage of prostate cancer. In cases of CRPC, the cancer exhibits limited responsiveness to therapies aimed at reducing testosterone levels. Indicators of progression, such as an increasing prostate-specific antigen (PSA) level, can occur despite diminished testosterone. Generally, CRPC is associated with a less favorable prognosis than hormone-sensitive prostate cancer, as it tends to be more aggressive and prone to metastasis. Current research efforts are directed toward elucidating the mechanisms underlying resistance to androgen deprivation and creating innovative treatment options that target these pathways.

Castrate Resistant Prostate Market- Market Dynamics

Increasing early detection of prostate cancer is expected to propel market growth.

Early detection facilitates prompt intervention through androgen deprivation therapies (ADT) or alternative treatments during the initial stages of prostate cancer. Nevertheless, certain cases will progress to castration-resistant prostate cancer (CRPC) despite initial therapies, yet early intervention may contribute to prolonged patient survival. While prostate cancer can pose significant health risks, the majority of men diagnosed with the disease do not succumb to it. According to the American Cancer Society, projections for prostate cancer in the United States for 2024 indicate approximately 299,010 new cases and around 35,250 fatalities attributed to the disease. Additionally, the emergence of novel therapies and advancements in diagnostic technologies may open new pathways for market expansion. However, limited awareness and diagnostic capabilities in developing regions could hinder market growth.

Castrate Resistant Prostate Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.70% over the forecast period (2024-2032)

Based on Therapy segmentation, Hormonal Therapy was the leading Drug Class in 2023

Based on region, North America was the leading revenue generator in 2023

Castrate Resistant Prostate Market- Segmentation Analysis:

The Global Castrate Resistant Prostate Market is segmented based on Therapy, Distribution channel, and Region.

The market is segmented into four distinct categories according to therapy type: Chemotherapy, Hormonal Therapy, Immunotherapy, and Radiotherapy. Hormonal Therapy holds a predominant position in the market. This form of therapy is essential in the management of Castrate-Resistant Prostate Cancer (CRPC), given that the progression of prostate cancer is primarily influenced by androgen hormones, particularly testosterone.

The market is segmented into four categories according to the Distribution Channel: Hospitals, Cancer Treatment Centers, Retail Pharmacies, and Online Pharmacies. Hospitals and cancer treatment centers continue to play a vital role in delivering advanced and specialized care, whereas retail and online pharmacies are increasingly significant as a growing number of patients opt for outpatient treatment management.

Castrate Resistant Prostate Market- Geographical Insights

This market is geographically extensive, encompassing North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These areas are further categorized based on the countries contributing to business activities. North America leads in market expansion, primarily due to rising healthcare expenditures and enhanced access to treatment options. The significant increase in healthcare spending in North America, especially in the United States and Canada, is crucial to the growth of the CRPC market. Elevated healthcare budgets facilitate greater investment in state-of-the-art medical treatments, advanced diagnostic tools, and innovative therapies for CRPC. According to National Health Expenditures, healthcare spending in the U.S. rose by 4.1% to USD 4.5 trillion in 2022, outpacing the 3.2% increase observed in 2021, although it remains considerably lower than the 10.6% surge in 2020. Europe ranks as the second-largest region for market growth, driven by a growing preference for outpatient care.

Castrate Resistant Prostate Market- Competitive Landscape:

The market for castrate-resistant prostate cancer (CRPC) is marked by significant competition among pharmaceutical and biopharmaceutical companies dedicated to the development and commercialization of innovative therapies. As numerous established treatments are already present, the market is experiencing a growing saturation, prompting companies to engage in vigorous marketing and promotional strategies to secure a larger share. The emphasis on combination therapies, genetic profiling, and immuno-oncology is expected to further influence the evolving competitive environment.

Recent Developments:

On September 30, 2019, findings released in the New England Journal of Medicine indicated that patients suffering from metastatic castration-resistant prostate cancer (mCRPC) who had previously undergone treatment with docetaxel and exhibited disease progression within 12 months while on an androgen receptor (AR)-targeted therapy (either abiraterone or enzalutamide) demonstrated a notably extended radiographic progression-free survival (rPFS) when treated with Jevtana (cabazitaxel) in combination with prednisone, in comparison to those receiving abiraterone plus prednisone or enzalutamide.

On January 24, 2024, Johnson & Johnson revealed that new clinical and real-world evidence will be presented in 18 abstracts at the upcoming ASCO GU Symposium, scheduled to take place in San Francisco from January 25 to 27. This announcement underscores the Company's dedication to advancing the research in genitourinary (GU) cancers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CASTRATE-RESISTANT PROSTATE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Pfizer, Inc.
  • Astellas Pharma, Inc.
  • Bayer AG
  • Phinergy
  • Others

GLOBAL CASTRATE RESISTANT PROSTATE MARKET, BY THERAPY- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
  • Radiotherapy

GLOBAL CASTRATE RESISTANT PROSTATE MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Cancer Treatment Centers
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CASTRATE RESISTANT PROSTATE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Castrate Resistant Prostate Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Castrate Resistant Prostate Market Snippet by Therapy
    • 2.1.2. Castrate Resistant Prostate Market Snippet by Distribution Channel
    • 2.1.3. Castrate Resistant Prostate Market Snippet by Country
    • 2.1.4. Castrate Resistant Prostate Market Snippet by Region
  • 2.2. Competitive Insights

3. Castrate Resistant Prostate Key Market Trends

  • 3.1. Castrate Resistant Prostate Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Castrate Resistant Prostate Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Castrate Resistant Prostate Market Opportunities
  • 3.4. Castrate Resistant Prostate Market Future Trends

4. Castrate Resistant Prostate Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Castrate Resistant Prostate Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Castrate Resistant Prostate Market Landscape

  • 6.1. Castrate Resistant Prostate Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Castrate Resistant Prostate Market - By Therapy

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy, 2022 & 2030 (%)
    • 7.1.2. Chemotherapy
    • 7.1.3. Hormonal Therapy
    • 7.1.4. Immunotherapy
    • 7.1.5. Radiotherapy

8. Castrate Resistant Prostate Market - By Distribution Channel

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 8.1.2. Hospitals
    • 8.1.3. Cancer Treatment Centers
    • 8.1.4. Retail Pharmacies
    • 8.1.5. Online Pharmacies

9. Castrate Resistant Prostate Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Castrate Resistant Prostate Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Castrate Resistant Prostate Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Castrate Resistant Prostate Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Castrate Resistant Prostate Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Castrate Resistant Prostate Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Castrate Resistant Prostate Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Sanofi
    • 10.2.2. Johnson & Johnson Services, Inc.
    • 10.2.3. Pfizer, Inc.
    • 10.2.4. Astellas Pharma, Inc.
    • 10.2.5. Bayer AG
    • 10.2.6. Phinergy
    • 10.2.7. Others

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us